Description générale
Ritonavir is recommended for use in combination with other protease inhibitors as a pharmacological booster in the prevention and treatment of HIV/AIDS, and not as an antiretroviral in its own right.
INN
Ritonavir
Codes ATC
Type de médicament
Chemical agent
Historique des statuts LME
Ajouté pour la première fois en 2002
(TRS
914)
pour
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified
Wikipédia
DrugBank
Recommandations
Section
Antiretrovirals > Protease inhibitors
- Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)